Peripheral Arterial Disease Clinical Trial
— STANDOfficial title:
A Clinical Evaluation of the MicroSTent® PeripherAl Vascular SteNt in Subjects With Arterial Disease Below the Knee (STAND)
This prospective pivotal study is a double arm, randomized multi-center study evaluating the safety and performance of the MicroStent peripheral vascular stent system for use in arterial lesions below the knee. A total of 177 subjects will be enrolled at up to 25 centers and followed for up to 3 years, with the primary safety and efficacy endpoints evaluated 30 days and 6 months, respectively, post-implant.
Status | Not yet recruiting |
Enrollment | 177 |
Est. completion date | August 2021 |
Est. primary completion date | January 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 21 Years to 90 Years |
Eligibility |
General Inclusion Criteria: 1. Subject is a male or a non-pregnant female adult between the age of 21 and 90 years old. 2. Subject has documented clinical evidence of critical limb ischemia (CLI) in the target limb prior to the index procedure, with a Rutherford Classification score of 4-5. 3. The subject, or subject's designated legal representative, has been informed of the nature of the study and is willing to provide written informed consent. 4. Subject is willing to comply with all required follow-up visits. 5. Subject life expectancy is =1 year per the Principal Investigator. Angiographic Inclusion Criteria: 6. Target vessel reconstitutes at or above the ankle with inline flow to at least one patent (<50% stenosis) inframalleolar outflow vessel. 7. Subject has a lesion, with = 70% stenosis and = 12.0 cm in length located at or distal to the tibial-peroneal trunk and above the tibiotalar joint; including the anterior tibial, posterior tibial or peroneal arteries. 8. Target lesion has a reference vessel diameter of 2.5 - 4.5 mm 9. The target lesion is able to be crossed with a guidewire to facilitate treatment with the randomized device. General Exclusion Criteria: 1. Subject had a prior or has a planned index limb amputation above the ankle. 2. Subject has a wound/ulcer on the forefoot with a surface area >4cm² or osteomyelitis involving the calcaneus bone. 3. Subject is pregnant, plans to become pregnant, or is nursing. 4. Subject has clinical conditions that severely inhibit X-ray or duplex ultrasound visualization (e.g. body habitus). 5. Subject has a history of hypercoagulation/clotting disorders or acute thrombosis. 6. Subject has allergy to iodinated contrast media that cannot be adequately managed with medication. 7. Subject is in acute renal failure. 8. Subject has an active systemic infection. 9. Subject is participating in another research study involving an investigational device, biologic, or drug that has not completed the primary endpoint at the time of randomization/enrollment. 10. Subject has other comorbidities that - in the opinion of the investigator - preclude them from receiving study treatment and/or from completing the required study follow-up assessments. 11. Subject presents with acute limb ischemia or acute thrombosis of the target limb. 12. Subject has experienced myocardial infarction, thrombolysis, or angina less than 30 days prior to the index procedure. 13. Subject had a stroke within 3 months of index procedure. Angiographic Exclusion Criteria: 14. Failure to successfully treat clinically significant inflow lesions in the ipsilateral iliac, femoral, or popliteal arteries. Successful treatment is defined as obtaining =30% residual stenosis with no major procedural complications (e.g embolism). 15. Failure to successfully treat significant non-target infra-popliteal lesions. Successful treatment is defined as obtaining =30% residual stenosis with no major procedural complications (e.g. embolism). 16. Target lesion is within a previously placed stent. |
Country | Name | City | State |
---|---|---|---|
United States | University of Maryland Medical Center | Baltimore | Maryland |
United States | Cardiovascular Associates of the Southeast | Birmingham | Alabama |
United States | Deborah Heart and Lung Center | Browns Mills | New Jersey |
United States | Rush University Medical Center | Chicago | Illinois |
United States | North Jersey Vascular Center | Clifton | New Jersey |
United States | Ohio Health Riverside Methodist | Columbus | Ohio |
United States | Midwest Cardiovascular Research Foundation | Davenport | Iowa |
United States | Advanced Cardiac and Vascular Amputation Prevention Center | Grand Rapids | Michigan |
United States | Cardiovascular Institute of the South | Houma | Louisiana |
United States | First Coast Cardiovascular Institute | Jacksonville | Florida |
United States | Premier Vascular Access and Imaging Center | Knoxville | Tennessee |
United States | AZH/WAVE Vascular Center | Milwaukee | Wisconsin |
United States | New York University - Langone Health | New York | New York |
United States | Einstein Heart and Vascular | Philadelphia | Pennsylvania |
United States | Rhode Island Hospital | Providence | Rhode Island |
United States | NC Heart and Vascular Research | Raleigh | North Carolina |
United States | Eastlake Cardiovascular | Roseville | Michigan |
United States | Advent Health Sebring | Sebring | Florida |
United States | Cardiovascular Associates of East Texas | Tyler | Texas |
Lead Sponsor | Collaborator |
---|---|
Micro Medical Solution, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Freedom from perioperative death (POD) | Primary Safety Endpoint | 30 days post index procedure | |
Primary | Freedom from major adverse limb event (MALE) | Primary Safety Endpoint | 6 months post index procedure | |
Primary | Freedom from major amputation | Primary Effectiveness Endpoint | 6 months post index procedure | |
Primary | Freedom from target lesion occlusion with no clinically driven target lesion reintervention (TLR) | Primary Effectiveness Endpoint | 6 months post index procedure | |
Secondary | Freedom from major adverse limb event (MALE) | Secondary Safety Endpoint #1 | 30 days, 3 months, 6 months, 1 year, 2 year, and 3 years post index procedure | |
Secondary | Frequency and severity of serious adverse events and device and procedure-related adverse events. | Secondary Safety Endpoint #2 | Post randomization, 30 days, 3 months, 6 months, 1 year, 2 year, and 3 years post randomization | |
Secondary | Freedom from major amputation (above the ankle) | Secondary Effectiveness Endpoint #1 | 6 months post index procedure | |
Secondary | Reduction in size of ischemic leg/foot ulcers | Secondary Effectiveness Endpoint #2 | 6 months post index procedure |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06032065 -
Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD (SMART PAD)
|
Phase 3 | |
Active, not recruiting |
NCT03987061 -
MOTIV Bioresorbable Scaffold in BTK Artery Disease
|
N/A | |
Recruiting |
NCT03506633 -
Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients
|
N/A | |
Active, not recruiting |
NCT03506646 -
Dietary Nitrate Supplementation and Thermoregulation
|
N/A | |
Active, not recruiting |
NCT04677725 -
NEtwork to Control ATherothrombosis (NEAT Registry)
|
||
Recruiting |
NCT05961943 -
RESPONSE-2-PAD to Reduce Sedentary Time in Peripheral Arterial Disease Patients
|
N/A | |
Recruiting |
NCT06047002 -
Personalised Antiplatelet Therapy for Patients With Symptomatic Peripheral Arterial Disease
|
||
Completed |
NCT03185052 -
Feasibility of Outpatient Care After Manual Compression in Patients Treated for Peripheral Arterial Disease by Endovascular Technique With 5F Sheath Femoral Approach
|
N/A | |
Recruiting |
NCT05992896 -
A Study of Loco-Regional Liposomal Bupivacaine Injection
|
Phase 4 | |
Completed |
NCT04635501 -
AbsorbaSeal (ABS 5.6.7) Vascular Closure Device Trial
|
N/A | |
Recruiting |
NCT04584632 -
The Efemoral Vascular Scaffold System (EVSS) for the Treatment of Patients With Symptomatic Peripheral Vascular Disease From Stenosis or Occlusion of the Femoropopliteal Artery
|
N/A | |
Withdrawn |
NCT03994185 -
The Merit WRAPSODY™ Endovascular Stent Graft for Treatment of Iliac Artery Occlusive Disease
|
N/A | |
Withdrawn |
NCT03538392 -
Serranator® Alto Post Market Clinical Follow Up (PMCF) Study
|
||
Recruiting |
NCT02915796 -
Autologous CD133(+) Cells as an Adjuvant to Below the Knee Percutaneous Transluminal Angioplasty
|
Phase 1 | |
Active, not recruiting |
NCT02900924 -
Observational Study to Evaluate the BioMimics 3D Stent System: MIMICS-3D
|
||
Completed |
NCT02901847 -
To Evaluate the Introduction of a Public Health Approach to Peripheral Arterial Disease (PAD) Using National Centre for Sport and Exercise Medicine Facilities.
|
N/A | |
Not yet recruiting |
NCT02455726 -
Magnesium Oral Supplementation to Reduce Pain Inpatients With Severe Peripheral Arterial Occlusive Disease
|
N/A | |
Withdrawn |
NCT02126540 -
Trial of Pantheris System, an Atherectomy Device That Provides Imaging While Removing Plaque in Lower Extremity Arteries
|
N/A | |
Not yet recruiting |
NCT02387450 -
Reduced Cardiovascular Morbi-mortality by Sildenafil in Patients With Arterial Claudication
|
Phase 2/Phase 3 | |
Completed |
NCT02384980 -
Saving Life and Limb: FES for the Elderly With PAD
|
Phase 1 |